Moderna Stock Is Trading Higher Today: What's Going On?
Moderna Inc (NASDAQ:MRNA) shares are trading higher on Monday. Piper Sandler boosted its price target on the stock to $69 from $63 while reiterating an Overweight rating. Here’s what you should know.
- Moderna shares are trending higher. Why is MRNA stock advancing?
Multiple Pipeline Catalysts Ahead
Piper Sandler expects Moderna to generate $2.07 billion in product sales in 2026, driven largely by its next‑generation COVID vaccine, mNEXSPIKE, according to Investing.com.
The FDA is set to review Moderna's biologics license application for its seasonal flu vaccine, mRNA‑1010, with an Aug. 5 PDUFA date.
Moderna's combination flu and COVID vaccine, mRNA‑1083, is currently under review in Europe and Canada. The company also expects interim Phase III data for its norovirus vaccine, mRNA‑1403, in 2026. All of these catalysts set the stock up for outperformance, according to analysts at Piper Sandler.
Moderna ended 2025 with $8.14 billion in cash. The company holds more cash than debt, giving it ample flexibility to fund its broad pipeline and advance multiple late‑stage programs simultaneously.
Moderna recently reported fourth‑quarter results that topped expectations. The company posted an EPS loss of $2.11, beating the forecasted loss of $2.62, while revenue reached $678 million, ahead of the $662.84 million estimate.
What Other Analysts Are Saying
Moderna has seen a variety of ratings in recent months from different financial analysis firms, with a general upward trend in target prices.
Earlier in February, Goldman Sachs and Evercore ISI Group also maintained their ratings at Neutral and In-Line respectively, with Goldman Sachs setting a target price of $41.00 (from $36.00) and Evercore setting the target at $35.00 (from $28.00). RBC Capital also held its rating at Sector Perform but raised the target price to $30.00 from $25.00. Interestingly, UBS downgraded Moderna from Buy to Neutral on Jan. 7 and lowered the target from $40.00 to $34.00.
MRNA Price Action: Moderna shares were up 1.08% at $50.41 at the time of publication on Monday, according to Benzinga Pro.
Image: Pcruciatti/Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Microsoft (MSFT.US) 365 services experience second major outage this year, affecting multiple government agencies and enterprises worldwide
Despite a "partial recovery," the latest Microsoft service outage continued into Asia-Pacific business hours.
Nvidia (NVDA.US) New CEO Candidates and Market Predictions: Trump Nominates Cook as Successor
As the successor remains uncertain, external voices have already begun to "make choices" for Nvidia.
Safe haven halo fails? US Treasury sell-off returns, Wall Street just breathed a sigh of relief and is startled again
Just as global bond investors began to believe that the worst phase of this year's sell-off had passed, the surge in U.S. Treasury yields has forced them to reassess that judgment.
Before the Jensen Huang scandal broke out, the Quant King precisely cleared out Nvidia!
The latest 13F filing shows that quantitative giant Renaissance Technologies almost completely sold off its holdings in Nvidia (reduced by 99.7%), Meta (reduced by 99.9%), as well as other tech giants like Apple and Amazon in the third quarter, and significantly reduced its position in Palantir. At the same time, it heavily increased its holdings in Micron Technology (up by 618.7%), AMD, and SanDisk, as well as other storage and chip stocks.
Crypto prices
More
